. "Alogliptin po akutn\u00EDm koron\u00E1rn\u00EDm syndromu u pacient\u016F s diabetes mellitus"@cs . "\u0160pinar, Jind\u0159ich" . . . "1801-1209" . "Alogliptin po akutn\u00EDm koron\u00E1rn\u00EDm syndromu u pacient\u016F s diabetes mellitus"@cs . "Diabetes mellitus type 2 (DM2) is a serious chronic disease with an increasing incidence in developed countries. About 8% of Czech population is suffering from diabetes; about 90% of them are DM2. The main aim of the treatment is the decrease of morbidity and mortality. The treatment based on lowering blood glues is not optimal yet. A possible optimal treatment is based on so called incretins. GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide, gastric inhibitory polypeptide) are the best known incretine hormones. Both of them are metabolized by the enzyme dipeptidyl peptidase 4 (DPP-4). The effect of drugs called gliptins is based on an inhibition of the enzyme dipeptidyl peptidase 4 (DPP-4). The EXAMINE study in patients with DM2 and after acute coronary syndrome randomized 5380 patients on the treatment with alogliptin or placebo; the patients were followed 40 months (median of treatment with alogliptin was 18 months)."@en . . . "\u0160pinarov\u00E1, Lenka" . . "CZ - \u010Cesk\u00E1 republika" . "Alogliptin po akutn\u00EDm koron\u00E1rn\u00EDm syndromu u pacient\u016F s diabetes mellitus" . "3"^^ . . . "alogliptin; acute coronary syndrome; HbA; .hypoglycaemia; pancreatitis"@en . "I" . "RIV/00216224:14110/14:00078560!RIV15-MSM-14110___" . "[081D0A672537]" . . . . "6"^^ . "3"^^ . . "Diabetes mellitus (DM) 2. typu je z\u00E1va\u017En\u00E9 chronick\u00E9 onemocn\u011Bn\u00ED, jeho\u017E v\u00FDskyt ve vysp\u011Bl\u00FDch zem\u00EDch neust\u00E1le nar\u016Fst\u00E1. V \u010Cesk\u00E9 republice nyn\u00ED trp\u00ED DM p\u0159ibli\u017En\u011B 8 % obyvatel, p\u0159i\u010Dem\u017E asi 90 % z nich tvo\u0159\u00ED pr\u00E1v\u011B nemocn\u00ED s DM 2. typu. Z\u00E1kladn\u00EDm c\u00EDlem l\u00E9\u010Dby diabet\u016F je sn\u00ED\u017Een\u00ED morbidity a mortality pacient\u016F. L\u00E9\u010Dba pacient\u016F s DM 2. typu je v sou\u010Dasnosti \u00FA\u010Dinn\u00E1 z pohledu sni\u017Eov\u00E1n\u00ED glykemie, ale bohu\u017Eel je\u0161t\u011B nen\u00ED zcela optim\u00E1ln\u00ED z pohledu morbidity a mortality. Jist\u00E9mu ide\u00E1lu se ji\u017E bl\u00ED\u017E\u00ED terapie zalo\u017Een\u00E1 na pod\u00E1v\u00E1n\u00ED inkretin\u016F. Jako inkretinov\u00E9 hormony, mezi n\u011B\u017E v sou\u010Dasn\u00E9 dob\u011B \u0159ad\u00EDme GLP-1 (glucagon-like peptide 1) a GIP (glucose-dependent insuli-notropic poiypeptide, gastric inhibitor polypeptide), jsou ozna\u010Dov\u00E1ny biochemick\u00E9 l\u00E1tky polypeptidick\u00E9 povahy. Oba inkretinov\u00E9 hormony, tedy GLP-1 i GIP, jsou v krevn\u00EDm ob\u011Bhu b\u011Bhem n\u011Bkolika m\u00E1lo minut odbour\u00E1v\u00E1ny enzymem dipeptidylpeptid\u00E1zou-4 (DPP-4). Mechanismus \u00FA\u010Dinku t\u011Bch\u00ACto l\u00E9\u010Div, naz\u00FDvan\u00FDch gliptiny, spo\u010D\u00EDv\u00E1 v inhibici DPP-4."@cs . "RIV/00216224:14110/14:00078560" . "Alogliptin after acute coronary syndrome in patients with diabetes mellitus"@en . "2014" . . "Suppl. 2" . "Farmakoterapie" . "14110" . . "Alogliptin po akutn\u00EDm koron\u00E1rn\u00EDm syndromu u pacient\u016F s diabetes mellitus" . . "Alogliptin after acute coronary syndrome in patients with diabetes mellitus"@en . . . "V\u00EDtovec, Ji\u0159\u00ED" . "2224" . "Diabetes mellitus (DM) 2. typu je z\u00E1va\u017En\u00E9 chronick\u00E9 onemocn\u011Bn\u00ED, jeho\u017E v\u00FDskyt ve vysp\u011Bl\u00FDch zem\u00EDch neust\u00E1le nar\u016Fst\u00E1. V \u010Cesk\u00E9 republice nyn\u00ED trp\u00ED DM p\u0159ibli\u017En\u011B 8 % obyvatel, p\u0159i\u010Dem\u017E asi 90 % z nich tvo\u0159\u00ED pr\u00E1v\u011B nemocn\u00ED s DM 2. typu. Z\u00E1kladn\u00EDm c\u00EDlem l\u00E9\u010Dby diabet\u016F je sn\u00ED\u017Een\u00ED morbidity a mortality pacient\u016F. L\u00E9\u010Dba pacient\u016F s DM 2. typu je v sou\u010Dasnosti \u00FA\u010Dinn\u00E1 z pohledu sni\u017Eov\u00E1n\u00ED glykemie, ale bohu\u017Eel je\u0161t\u011B nen\u00ED zcela optim\u00E1ln\u00ED z pohledu morbidity a mortality. Jist\u00E9mu ide\u00E1lu se ji\u017E bl\u00ED\u017E\u00ED terapie zalo\u017Een\u00E1 na pod\u00E1v\u00E1n\u00ED inkretin\u016F. Jako inkretinov\u00E9 hormony, mezi n\u011B\u017E v sou\u010Dasn\u00E9 dob\u011B \u0159ad\u00EDme GLP-1 (glucagon-like peptide 1) a GIP (glucose-dependent insuli-notropic poiypeptide, gastric inhibitor polypeptide), jsou ozna\u010Dov\u00E1ny biochemick\u00E9 l\u00E1tky polypeptidick\u00E9 povahy. Oba inkretinov\u00E9 hormony, tedy GLP-1 i GIP, jsou v krevn\u00EDm ob\u011Bhu b\u011Bhem n\u011Bkolika m\u00E1lo minut odbour\u00E1v\u00E1ny enzymem dipeptidylpeptid\u00E1zou-4 (DPP-4). Mechanismus \u00FA\u010Dinku t\u011Bch\u00ACto l\u00E9\u010Div, naz\u00FDvan\u00FDch gliptiny, spo\u010D\u00EDv\u00E1 v inhibici DPP-4." . .